{"id":5600,"date":"2026-01-06T22:30:56","date_gmt":"2026-01-06T17:00:56","guid":{"rendered":"https:\/\/vajiramandravi.com\/upsc-exam\/?p=5600"},"modified":"2026-01-07T10:37:18","modified_gmt":"2026-01-07T05:07:18","slug":"covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/upsc-exam\/covid-19-vaccine\/","title":{"rendered":"Covid-19 Vaccines"},"content":{"rendered":"

The COVID-19 vaccines<\/strong> represent a significant achievement in the history of medical science. Developed in response to the global pandemic caused by the SARS-CoV-2 virus,<\/strong> these vaccines were designed at an unprecedented pace <\/strong>and yet underwent rigorous testing to ensure their safety and efficacy. Leveraging various technologies, from mRNA platforms to viral vector and protein subunit approaches<\/strong>, these vaccines have been instrumental in curbing the spread of the virus, reducing severe disease, and saving countless lives. They acted as a pivotal tool in the world's collective effort to end the pandemic and restore normalcy to societies worldwide.<\/p>\r\n

Background of Covid-19 Vaccine<\/h2>\r\n

In 2020, COVID-19 caused by the SARS-CoV-2 virus emerged as a global pandemic<\/strong> with significant health and socio-economic impacts. This necessitated the development of a vaccine.<\/p>\r\n

Need for the Development of Covid-19 Vaccine<\/strong><\/h3>\r\n

The world has faced several pandemics, however, vaccines were not made for each of them. But in the case of the COVID-19 pandemic, there were several reasons responsible for the development of COVID-19 vaccines such as:<\/p>\r\n

    \r\n\t
  • Transmission dynamics: <\/strong>SARS-CoV-2 has a high transmission rate<\/strong>, with many cases spread by asymptomatic or pre-symptomatic individuals, thereby making containment a challenging task.<\/li>\r\n\t
  • Overwhelmed healthcare systems:<\/strong> Rapid spread led to overwhelmed hospitals and healthcare providers, leading to scenarios where individuals were not able to receive adequate care.<\/li>\r\n\t
  • Comorbidities: <\/strong>People with underlying health conditions like obesity, diabetes, cardiovascular diseases, etc were at larger risk and in the absence of an established treatment procedure were at larger risk.<\/li>\r\n\t
  • Variants of concern: <\/strong>Multiple variants of the virus have emerged, some of which are associated with increased transmissibility, altered disease severity, or reduced vaccine efficacy.<\/li>\r\n\t
  • Economic impact: <\/strong>The pandemic led to unprecedented global economic downturns, necessitating a swift medical solution to allow a return to normalcy.<\/li>\r\n\t
  • Public pressure: <\/strong>The daily toll on lives and healthcare systems generated immense public demand for a vaccine.<\/li>\r\n<\/ul>\r\n

    Types of Covid-19 Vaccines<\/h2>\r\n

    Several vaccines for COVID-19 developed are mentioned below:<\/p>\r\n

    \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
    About<\/strong><\/td>\r\nType<\/strong><\/td>\r\nMechanism<\/strong><\/td>\r\n<\/tr>\r\n
    Pfizer-BioNTech (Comirnaty)<\/strong><\/td>\r\nmRNA vaccine<\/td>\r\nIntroduces a piece of genetic code (mRNA) that prompts cells to produce a protein resembling the spike protein of SARS-CoV-2.<\/td>\r\n<\/tr>\r\n
    Moderna (Spikevax)<\/strong><\/td>\r\nmRNA vaccine<\/td>\r\nUses mRNA to induce cells to produce a version of the spike protein.<\/td>\r\n<\/tr>\r\n
    AstraZeneca (Vaxzevria) <\/strong>(Known as Covisheild <\/strong>in India)<\/td>\r\nViral vector vaccine<\/td>\r\nUses a modified version of a different virus (chimpanzee adenovirus) to deliver a piece of genetic material from SARS-CoV-2.<\/td>\r\n<\/tr>\r\n
    Sinopharm<\/strong><\/td>\r\nInactivated virus vaccine<\/td>\r\nUses a virus that has been killed so it cannot cause disease but can still prompt an immune response.<\/td>\r\n<\/tr>\r\n
    Sputnik V<\/strong><\/td>\r\nViral vector vaccine<\/td>\r\nUses two different adenoviruses for the first and second doses to introduce SARS-CoV-2 genetic material.<\/td>\r\n<\/tr>\r\n
    Johnson & Johnson's Janssen<\/strong><\/td>\r\nViral vector vaccine<\/td>\r\nUses a human adenovirus to introduce a piece of SARS-CoV-2 genetic material.<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<\/figure>\r\n

    India and COVID-19 Vaccine Development<\/h2>\r\n

    India, a global pharmaceutical powerhouse,<\/strong> spearheaded COVID-19 vaccine development, producing indigenous vaccines like Covaxin <\/strong>and facilitating large-scale manufacturing of global candidates, reinforcing its pivotal role in global health solutions.<\/strong><\/p>\r\n

    Vaccines Developed in India<\/strong><\/h3>\r\n

    India has been at the forefront of the global COVID-19 vaccine development and production efforts. Major vaccines developed in India are:<\/p>\r\n

    \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
    Vaccine Name\u00a0<\/strong><\/td>\r\nDeveloped by<\/strong><\/td>\r\nType<\/strong><\/td>\r\nMechanism<\/strong><\/td>\r\n<\/tr>\r\n
    Covaxin<\/strong><\/td>\r\nBharat Biotech<\/strong>, ICMR and National Institute of Virology<\/td>\r\nInactivated virus vaccine<\/td>\r\nCovaxin uses a sample of the coronavirus that has been killed so that it cannot infect cells or replicate but can still trigger an immune response.<\/td>\r\n<\/tr>\r\n
    Covovax<\/strong><\/td>\r\nNovavax but manufactured by Serum <\/strong>Institute of India (SII)<\/td>\r\nProtein subunit vaccine.<\/td>\r\n\r\n

    - It uses a spike protein of the SARS-CoV-2 virus to stimulate an immune response.<\/p>\r\n

    - It also contains an adjuvant to boost this response<\/p>\r\n<\/td>\r\n<\/tr>\r\n

    ZyCoV-D<\/strong><\/td>\r\nZydus Cadila.<\/td>\r\nDNA-based vaccine.<\/td>\r\n\r\n

    - It is a plasmid DNA vaccine that, when administered, instructs the human cells to produce the spike protein of the SARS-CoV-2 virus.<\/p>\r\n

    - This, in turn, elicits an immune response in the body.<\/p>\r\n<\/td>\r\n<\/tr>\r\n

    \r\n

    Incovacc<\/strong><\/p>\r\n

    (Nasal Vaccine)\u00a0<\/strong><\/p>\r\n<\/td>\r\n

    		Bharat Biotech, <\/strong>Precision Virologics and the Washington University School of Medicine<\/td>\r\nRecombinant replication-deficient adenovirus vectored vaccine<\/td>\r\nIt stimulates an immune response in the mucosal membrane, potentially producing antibodies in the upper respiratory tract that can reduce infection and transmission.<\/td>\r\n<\/tr>\r\n
    Corbevax (Booster Dose)\u00a0<\/strong><\/td>\r\nBiological E Limited<\/td>\r\nRecombinant protein sub-unit<\/td>\r\nSpike protein is introduced into the body by itself, without the rest of the virus, it doesn't cause harm but triggers an immune response<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<\/figure>\r\n

    Araogya Setu<\/strong><\/h3>\r\n

    To aid in the fight against COVID-19 in India, the government developed Aarogya Setu, a smartphone app. This smartphone app combines GPS and Bluetooth to track the virus and determine whether or not someone has been in contact with an infected person. Key features include:<\/p>\r\n

      \r\n\t
    • COVID-19 cases and updates:<\/strong> Aarogya Setu tracks the number of COVID-19 cases in India, including new cases, recoveries, and deaths. This tool keeps users informed about COVID-19 trends and its national impact.<\/li>\r\n\t
    • Self-assessment:<\/strong> A key element of the software is the self-assessment tool. Users can quickly self-assess by answering questions about their symptoms, travel history, and COVID-19 exposure. Based on responses, the app calculates a risk score and advises users on medical advice or precautions.<\/li>\r\n\t
    • Covid-19 testing centers:<\/strong> Aarogya Setu helps consumers find nearby testing centers. This information helps people discover testing facilities if they suspect virus exposure or symptoms.<\/li>\r\n\t
    • COVID-19 helpline and resources:<\/strong> The app lists government helplines and assistance services. Emergency helplines, state-specific helplines, and other tools can help users report COVID-19 concerns.<\/li>\r\n\t
    • Safety guidelines and best practices: <\/strong>Aarogya Setu provides health authorities' COVID-19 prevention guidelines. These instructions encompass masks, hand hygiene, social distancing, and other precautions.\r\n\r\n
        \r\n\t
      • Users can obtain quarantine protocols to learn how to self-isolate owing to exposure or travel history.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
      • Vaccination: <\/strong>The app provides information about the Indian COVID-19 vaccination push, including eligibility criteria, vaccination centers, and registration.<\/li>\r\n<\/ul>\r\n

        India\u2019s Vaccination Strategy<\/strong><\/h3>\r\n

        India faced a humongous task of vaccinating over 1 billion population. However, with the effective use of ICT<\/strong> and efficient planning and implementation, India achieved a big milestone of administering over 220 crore vaccine doses. Key aspects of India\u2019s strategy were:<\/p>\r\n

          \r\n\t
        • Phased approach: <\/strong>The drive began with healthcare and frontline workers, followed by those above 60 years, and then those above 45 years with co-morbidities.<\/li>\r\n\t
        • Co-WIN platform: <\/strong>A digital platform for real-time monitoring of vaccine delivery, registration, and scheduling for beneficiaries, and for reporting adverse events.<\/li>\r\n\t
        • Decentralized delivery: <\/strong>Both government and private sector health facilities were used as vaccination centers.<\/li>\r\n\t
        • AEFI (Adverse Event Following Immunization) monitoring:<\/strong> A surveillance system to monitor and address any side effects or adverse reactions post-vaccination.<\/li>\r\n\t
        • Equitable distribution<\/strong>: Ensuring that vaccines reach every state and union territory in proportion to their population and the number of cases.<\/li>\r\n\t
        • Continuous review and feedback loop: <\/strong>Regular reviews of the vaccination strategy to address any challenges and feedback from the ground level.<\/li>\r\n\t
        • Diversified Vaccine portfolio: <\/strong>Granting emergency use authorization to multiple vaccines to ensure a broad supply.<\/li>\r\n\t
        • Community engagement: <\/strong>Engaging with community influencers, leaders, and organizations for widespread advocacy and acceptance of the vaccine.<\/li>\r\n<\/ul>\r\n

          Vaccine Maitri<\/strong><\/h3>\r\n
            \r\n\t
          • Meaning: <\/strong>A facet of global health diplomacy where nations use vaccine development\/delivery to enhance ties with other countries.<\/li>\r\n\t
          • Importance of India\u2019s vaccine diplomacy:<\/strong>\r\n
              \r\n\t
            • Strategic:<\/strong>\r\n
                \r\n\t
              • Earn long-term goodwill by assisting neighbouring countries.<\/li>\r\n\t
              • Aligns with India\u2019s \"neighbourhood first\" initiative.<\/li>\r\n\t
              • Counter China\u2019s vaccine diplomacy in the region.<\/li>\r\n\t
              • Gain leverage as Western countries focus on their issues.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
              • Economic:<\/strong>\r\n
                  \r\n\t
                • Position India as a global vaccine supply hub.<\/li>\r\n\t
                • Boost pharmaceutical manufacturing in India.<\/li>\r\n\t
                • Enhance India's GDP by becoming a primary vaccine manufacturer.<\/li>\r\n\t
                • Rescue from Vaccine Cold War<\/strong>: India's early shipments counteract the US-China vaccine distribution tug-of-war.<\/li>\r\n\t
                • Earning moral right:<\/strong> India's actions contrast with criticisms of rich countries\u2019 vaccine distribution priorities.<\/li>\r\n\t
                • Disrupting Vaccine Nationalism: <\/strong>India's distribution disrupts the trend of countries prioritizing their citizens over others.<\/li>\r\n\t
                • Facilitating global collaboration: <\/strong>India supports global efforts, notably the WHO-backed COVAX Facility.<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n

                  Significance of Covid-19 Vaccine<\/h2>\r\n

                  The COVID-19 vaccines represent a critical step in fighting the pandemic, significantly lessening disease impact. Several benefits associated with COVID-19 vaccines are:<\/p>\r\n

                    \r\n\t
                  • Prevention of Severe Disease and Death<\/strong>\r\n
                      \r\n\t
                    • Reduction in mortality:<\/strong> Dramatic decrease in COVID-19-related deaths among vaccinated populations.<\/li>\r\n\t
                    • Lower hospitalization rates:<\/strong> Vaccinated individuals are less likely to require hospital care if infected.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
                    • Curbing the Spread<\/strong>\r\n
                        \r\n\t
                      • Community immunity: <\/strong>Reduced transmission rates help approach herd immunity.<\/li>\r\n\t
                      • Protection of the vulnerable: <\/strong>Vaccinating a majority indirectly protects those who can't be vaccinated.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
                      • Economic Revival<\/strong>\r\n
                          \r\n\t
                        • Reopening economies:<\/strong> As more people get vaccinated, businesses and markets can reopen safely.<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n

                          Employment:<\/strong> Resumption of work leading to reduced unemployment rates.<\/p>\r\n

                            \r\n\t
                          • Travel resumption:<\/strong> Eased travel restrictions and quarantines for vaccinated travellers.<\/li>\r\n\t
                          • Psychological and Mental Health Benefits<\/strong>\r\n
                              \r\n\t
                            • Reduced anxiety:<\/strong> Lesser fear of contracting severe disease.<\/li>\r\n\t
                            • Social interaction: <\/strong>Human connections and interactions vital for mental well-being resume.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
                            • Research and Scientific Collaboration<\/strong>\r\n
                                \r\n\t
                              • Global collaboration: <\/strong>Countries collaborated for vaccine research and distribution.<\/li>\r\n\t
                              • Rapid advancements<\/strong>: Demonstrated potential for quick scientific solutions in emergencies.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
                              • Political and Diplomatic Cooperation<\/strong>\r\n
                                  \r\n\t
                                • Vaccine diplomacy: <\/strong>Nations helping others by providing vaccines, and fostering cooperation.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
                                • Preparedness for Future Pandemics<\/strong>\r\n
                                    \r\n\t
                                  • Research base:<\/strong> The rapid vaccine development sets a precedent for future challenges.<\/li>\r\n\t
                                  • Infrastructure development: <\/strong>Better-equipped labs and research facilities for the future.<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n

                                    Challenges associated with Covid-19 Vaccines<\/h2>\r\n

                                    COVID-19 vaccines, while groundbreaking, faced hurdles in development, distribution, and acceptance, highlighting the complexities of global health interventions during unprecedented times. Several challenges associated with Covid-19 vaccines were:<\/p>\r\n

                                      \r\n\t
                                    • Production and Supply Chain Issues<\/strong>\r\n
                                        \r\n\t
                                      • Scaling production: <\/strong>Rapidly increasing manufacturing capacity to meet global demand.<\/li>\r\n\t
                                      • Raw materials<\/strong>: Shortages of essential vaccine components.<\/li>\r\n\t
                                      • Logistics:<\/strong> Ensuring cold storage and timely distribution.<\/li>\r\n\t
                                      • Efficacy and Variants<\/strong><\/li>\r\n\t
                                      • Variable efficacy:<\/strong> Different vaccines show varied efficacy rates.<\/li>\r\n\t
                                      • Emerging variants: <\/strong>Some variants reduce vaccine effectiveness, necessitating updates and boosters.<\/li>\r\n\t
                                      • Administration and Distribution<\/strong><\/li>\r\n\t
                                      • Cold storage<\/strong>: Some vaccines require ultra-cold storage, complicating distribution.<\/li>\r\n\t
                                      • Equitable distribution:<\/strong> Ensuring vaccines reach all countries, especially low-income nations.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
                                      • Acceptance and Hesitancy<\/strong>\r\n
                                          \r\n\t
                                        • Misinformation:<\/strong> Addressing false information and conspiracy theories.<\/li>\r\n\t
                                        • Vaccine trust:<\/strong> Building and maintaining public trust in vaccine safety and efficacy.<\/li>\r\n\t
                                        • Safety Concerns and Monitoring<\/strong><\/li>\r\n\t
                                        • Side effects: <\/strong>Addressing and monitoring both common and rare side effects.<\/li>\r\n\t
                                        • Long-term data: <\/strong>Accumulating long-term safety and efficacy data.<\/li>\r\n\t
                                        • Regulatory and Approval Hurdles<\/strong><\/li>\r\n\t
                                        • Emergency use<\/strong>: Many vaccines were initially approved for emergency use, requiring further study for full approval.<\/li>\r\n\t
                                        • Global standards: <\/strong>Varied approval processes and standards across countries.<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t
                                        • Economic and Political Challenges<\/strong>\r\n
                                            \r\n\t
                                          • Cost barriers:<\/strong> Making vaccines affordable or free for all.<\/li>\r\n\t
                                          • Geopolitical tensions:<\/strong> Vaccine diplomacy and potential misuse for political leverage.<\/li>\r\n\t
                                          • Future Preparedness<\/strong><\/li>\r\n\t
                                          • Long-term strategy:<\/strong> Determining the need for booster shots and updated vaccines.<\/li>\r\n\t
                                          • Infrastructure:<\/strong> Building a resilient global infrastructure for potential future pandemics.<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n

                                            Covid-19 Vaccines UPSC\u00a0PYQs<\/h2>\r\n

                                            Question 1:<\/strong> In the context of vaccines manufactured to prevent Covid-19 pandemic, consider the following statements:<\/p>\r\n

                                              \r\n\t
                                            1. The Serum Institute of India produced a COVID-19 vaccine named Covishield using mRNA platform.<\/li>\r\n\t
                                            2. The Sputnik V vaccine is manufactured using a vector-based platform.<\/li>\r\n\t
                                            3. COVAXIN is an inactivated pathogen-based vaccine.<\/li>\r\n<\/ol>\r\n

                                              Which of the statements given above are correct?<\/p>\r\n

                                                \r\n\t
                                              1. 1 and 2 only<\/li>\r\n\t
                                              2. 2 and 3 only<\/li>\r\n\t
                                              3. 1 and 3 only<\/li>\r\n\t
                                              4. 1, 2 and 3<\/li>\r\n<\/ol>\r\n

                                                Answer: (b)<\/strong><\/p>","protected":false},"excerpt":{"rendered":"

                                                COVID-19 vaccines provide immunity against the coronavirus, significantly reducing illness severity, hospitalizations, and transmission rates globally.<\/p>\n","protected":false},"author":6,"featured_media":20253,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[239],"tags":[874,40],"class_list":{"0":"post-5600","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-quest-level-4","8":"tag-covid-19-vaccines","9":"tag-quest"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/posts\/5600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/comments?post=5600"}],"version-history":[{"count":1,"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/posts\/5600\/revisions"}],"predecessor-version":[{"id":20000,"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/posts\/5600\/revisions\/20000"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/media\/20253"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/media?parent=5600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/categories?post=5600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/upsc-exam\/wp-json\/wp\/v2\/tags?post=5600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}